Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit

Rhea-AI Summary

Seres Therapeutics, Inc. (Nasdaq: MCRB) will have President and CEO Eric Shaff present at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The presentation will be pre-recorded and accessible on Seres' website at 8:00 a.m. ET on the same day, remaining available for 21 days. Seres is known for its groundbreaking work in microbiome therapies, including the SER-109 program, which targets recurrent C. difficile infections and has received Breakthrough Therapy designation from the FDA. The company is also advancing several other therapeutic candidates for gastrointestinal diseases.

Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.

The pre-recorded presentation will be made available under the “Investors and Media” section of Seres’ website on Thursday, April 22, 2021 at 8:00 a.m. ET and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005172/en/

FAQ

What is Seres Therapeutics presenting at the Jefferies Summit 2021?

Seres Therapeutics will have a presentation by CEO Eric Shaff at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021.

When will the Seres Therapeutics presentation be available?

The presentation will be available on Seres' website starting April 22, 2021, at 8:00 a.m. ET and will be archived for approximately 21 days.

What is the SER-109 program by Seres Therapeutics?

SER-109 is a targeted microbiome drug candidate aimed at treating recurrent C. difficile infections and has received Breakthrough Therapy designation from the FDA.

What FDA designations has Seres Therapeutics received for its programs?

Seres Therapeutics has received Breakthrough Therapy and Orphan Drug designations for SER-109, and Fast Track and Orphan Drug designations for SER-287.

What other therapies is Seres Therapeutics developing?

In addition to SER-109, Seres is developing SER-287 for ulcerative colitis and SER-155 for gastrointestinal infections and related complications.